Sabine C. de Greeff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sabine C. de Greeff has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Annelot F. Schoffelen
Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
10 shared publications - Daan W. Notermans
Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands
7 shared publications - Cornelia C. H. Wielders
Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
6 shared publications - Eduard J. Kuijper
Leiden University Center of Infectious Diseases (LUCID), Leiden University Medical Center
4 shared publications - Romy Daniëlle Zwittink
National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
4 shared publications - Sandra Witteveen
Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands
4 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (28) , 2500881
National automated surveillance of hospital onset bacteraemia and fungaemia using data from the national antimicrobial resistance surveillance system: a retrospective exploratory evaluation, the Netherlands, 2018 to 2023
BACKGROUND: Hospital-onset bacteraemia and fungaemia (HOB) is a new target for automated surveillance of healthcare-associated infections. AIM: We aimed to evaluate (i) whether data from a national laboratory-based antimicrobial resistance (AMR) surveillance system (ISIS-AR) are a suitable source for fully automated HOB surveillance and (ii) whether the derived HOB rates from automated surveillance are a useful measure for national surveillance. METHODS: We applied an algorithm based on a consensus HOB definition to ISIS-AR data from 2018 to 2023. We performed: (i) technical evaluation of the data to determine their suitability for automated HOB surveillance, (ii) outcome validation of automatically identified HOB cases in four hospitals, and (iii) qualitative interviews with stakeholders on the anticipated value of HOB surveillance. RESULTS: Most parameters required for HOB identification were present, except for hospital admission dates (≥ 80% available in only 14 hospitals). Outcome validation showed accurate identification of HOBs caused by pathogens (non-commensals), but identification of HOBs caused by common commensals varied between hospitals, reflecting laboratory policy differences. Interviewees emphasised that feedback from national HOB surveillance to hospitals can be valuable for monitoring local trends, as signal for in-depth investigations and benchmarking. CONCLUSION: Dutch national automated HOB surveillance based on secondary use of national AMR surveillance data for pathogen-related HOBs is feasible, particularly if recording admission date is improved. Understanding local routine care and diagnostic practices is crucial for the interpretation of results. The main usefulness is expected at hospital level, while its value for national trend monitoring needs further study.
- 16 July 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (28) , 2500881
Open AccessNational automated surveillance of hospital onset bacteraemia and fungaemia using data from the national antimicrobial resistance surveillance system: a retrospective exploratory evaluation, the Netherlands, 2018 to 2023
BACKGROUND: Hospital-onset bacteraemia and fungaemia (HOB) is a new target for automated surveillance of healthcare-associated infections. AIM: We aimed to evaluate (i) whether data from a national laboratory-based antimicrobial resistance (AMR) surveillance system (ISIS-AR) are a suitable source for fully automated HOB surveillance and (ii) whether the derived HOB rates from automated surveillance are a useful measure for national surveillance. METHODS: We applied an algorithm based on a consensus HOB definition to ISIS-AR data from 2018 to 2023. We performed: (i) technical evaluation of the data to determine their suitability for automated HOB surveillance, (ii) outcome validation of automatically identified HOB cases in four hospitals, and (iii) qualitative interviews with stakeholders on the anticipated value of HOB surveillance. RESULTS: Most parameters required for HOB identification were present, except for hospital admission dates (≥ 80% available in only 14 hospitals). Outcome validation showed accurate identification of HOBs caused by pathogens (non-commensals), but identification of HOBs caused by common commensals varied between hospitals, reflecting laboratory policy differences. Interviewees emphasised that feedback from national HOB surveillance to hospitals can be valuable for monitoring local trends, as signal for in-depth investigations and benchmarking. CONCLUSION: Dutch national automated HOB surveillance based on secondary use of national AMR surveillance data for pathogen-related HOBs is feasible, particularly if recording admission date is improved. Understanding local routine care and diagnostic practices is crucial for the interpretation of results. The main usefulness is expected at hospital level, while its value for national trend monitoring needs further study.
- Open Access
- 25 June 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (25)
Ongoing multi-country outbreak of carbapenem-resistant Enterobacter hormaechei ST1344 carrying bla NDM-5 in the European Union/European Economic Area, March 2025 to April 2026
In seven EU/EEA countries, the emergence of NDM-5-producing Enterobacter hormaechei ST1344 among patients has been detected. In minimum spanning tree analysis of core genome-multilocus sequence-typing (cgMLST) profiles, isolates cluster with ≤ 4 allelic differences. The outbreak includes 57 cases (29 female/28 male; median age: 73 years), which occurred between March 2025 and April 2026. Many were hospitalised (n = 45), some with extensive prior medical treatment, and only three reported travel abroad. A cross-border investigation, including coordinated exposure questionnaires, has not yet identified a source.
- 25 June 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (25)
Open AccessOngoing multi-country outbreak of carbapenem-resistant Enterobacter hormaechei ST1344 carrying bla NDM-5 in the European Union/European Economic Area, March 2025 to April 2026
In seven EU/EEA countries, the emergence of NDM-5-producing Enterobacter hormaechei ST1344 among patients has been detected. In minimum spanning tree analysis of core genome-multilocus sequence-typing (cgMLST) profiles, isolates cluster with ≤ 4 allelic differences. The outbreak includes 57 cases (29 female/28 male; median age: 73 years), which occurred between March 2025 and April 2026. Many were hospitalised (n = 45), some with extensive prior medical treatment, and only three reported travel abroad. A cross-border investigation, including coordinated exposure questionnaires, has not yet identified a source.
- Open Access
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0260225
Comparative genomic surveillance of carbapenem-resistant Acinetobacter baumannii in the Netherlands in 2015–2017 and 2022–2024
We investigated the genomic epidemiology of carbapenem-resistant Acinetobacter baumannii (CRAb) during two surveillance periods: 2015–2017 (pilot 1) and 2022–2024 (pilot 2) in an international context to identify potential circulating high-risk lineages in the Netherlands. A total of 204 CRAb isolates were all analyzed by the carbapenem inactivation method, meropenem Etest, and whole-genome sequencing (combining Illumina and Nanopore). Comparative resistome, multilocus sequence typing (MLST), and whole-genome MLST (wgMLST) analyses were performed between pilots and compared to 577 international CRAb genomes. The Dutch CRAb population remained genetically diverse and stable between pilots and was dominated by international clone (IC)2 (61.8%), followed by IC9 (11.3%), IC1 (6.4%), and IC6 (5.9%). Also, epidemiological and clinical characteristics remained stable across both pilots. In contrast, CRAb in patients from Ukraine was genetically diverse and an epidemiologically distinct group. wgMLST indicated an increase in genetic clustering in 2022–2024, with unique CRAb clusters associated with Ukrainian patients. Of 26 identified clusters, 69% were linked to international sources. Differences in resistomes were observed between CRAb in patients from the Netherlands and Ukraine, and between pilots. Overall, 75% of isolates harbored bla OXA-23 -like genes, and bla NDM genes increased from 16% to 21%. None of the CRAb isolates from Ukrainian patients carried bla NDM genes; instead, they harbored bla OXA-23 -like and bla OXA-24 -like genes. Hybrid assemblies showed that carbapenemase genes were predominantly chromosomal. In conclusion, CRAb in the Netherlands showed genetic stability over time, yet the presence of New Delhi metallo-β-lactamase-carbapenemases and import of strains from high-risk regions underline the necessity for ongoing national surveillance. IMPORTANCE: In 2015–2017 and 2022–2024, pilot surveillance of carbapenem-resistant Acinetobacter baumannii (CRAb) was performed in the Netherlands. Three distinct groups were compared based on epidemiological and genomic data: CRAb from 2015 to 2017 and for the 2022–2024 period, CRAb in patients from the Netherlands, and CRAb in patients from Ukraine in the Netherlands. The genomic epidemiology of CRAb has been mostly stable between 2015–2017 and 2022–2024 but seems to be strongly affected by the introduction of CRAb from foreign countries. A proportion of the 2022–2024 isolates were from Ukrainian patients. The resistance genes of CRAb from Ukrainian patients were different from those of the Netherlands. CRAb in the Netherlands are acquiring New Delhi metallo-β-lactamase-carbapenemase genes, aided by the introduction of CRAb from foreign countries. Healthcare professionals should remain aware of the risk of hospitalization in a high-risk country and the potential secondary transmission of CRAb to patients in countries with a low prevalence of this organism.
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0260225
Open AccessComparative genomic surveillance of carbapenem-resistant Acinetobacter baumannii in the Netherlands in 2015–2017 and 2022–2024
We investigated the genomic epidemiology of carbapenem-resistant Acinetobacter baumannii (CRAb) during two surveillance periods: 2015–2017 (pilot 1) and 2022–2024 (pilot 2) in an international context to identify potential circulating high-risk lineages in the Netherlands. A total of 204 CRAb isolates were all analyzed by the carbapenem inactivation method, meropenem Etest, and whole-genome sequencing (combining Illumina and Nanopore). Comparative resistome, multilocus sequence typing (MLST), and whole-genome MLST (wgMLST) analyses were performed between pilots and compared to 577 international CRAb genomes. The Dutch CRAb population remained genetically diverse and stable between pilots and was dominated by international clone (IC)2 (61.8%), followed by IC9 (11.3%), IC1 (6.4%), and IC6 (5.9%). Also, epidemiological and clinical characteristics remained stable across both pilots. In contrast, CRAb in patients from Ukraine was genetically diverse and an epidemiologically distinct group. wgMLST indicated an increase in genetic clustering in 2022–2024, with unique CRAb clusters associated with Ukrainian patients. Of 26 identified clusters, 69% were linked to international sources. Differences in resistomes were observed between CRAb in patients from the Netherlands and Ukraine, and between pilots. Overall, 75% of isolates harbored bla OXA-23 -like genes, and bla NDM genes increased from 16% to 21%. None of the CRAb isolates from Ukrainian patients carried bla NDM genes; instead, they harbored bla OXA-23 -like and bla OXA-24 -like genes. Hybrid assemblies showed that carbapenemase genes were predominantly chromosomal. In conclusion, CRAb in the Netherlands showed genetic stability over time, yet the presence of New Delhi metallo-β-lactamase-carbapenemases and import of strains from high-risk regions underline the necessity for ongoing national surveillance. IMPORTANCE: In 2015–2017 and 2022–2024, pilot surveillance of carbapenem-resistant Acinetobacter baumannii (CRAb) was performed in the Netherlands. Three distinct groups were compared based on epidemiological and genomic data: CRAb from 2015 to 2017 and for the 2022–2024 period, CRAb in patients from the Netherlands, and CRAb in patients from Ukraine in the Netherlands. The genomic epidemiology of CRAb has been mostly stable between 2015–2017 and 2022–2024 but seems to be strongly affected by the introduction of CRAb from foreign countries. A proportion of the 2022–2024 isolates were from Ukrainian patients. The resistance genes of CRAb from Ukrainian patients were different from those of the Netherlands. CRAb in the Netherlands are acquiring New Delhi metallo-β-lactamase-carbapenemase genes, aided by the introduction of CRAb from foreign countries. Healthcare professionals should remain aware of the risk of hospitalization in a high-risk country and the potential secondary transmission of CRAb to patients in countries with a low prevalence of this organism.
- Open Access
- 30 October 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (6) , dlaf229
Increasing trend in fusidic acid resistance among MRSA isolates in the Netherlands, 2016–23
Objectives: Recently, several MRSA community outbreaks occurred in the Netherlands, including one caused by an impetigo-causing MRSA strain resistant to fusidic acid. Since fusidic acid and flucloxacillin are the main treatment options for impetigo, increasing resistance limits treatment possibilities. We examined trends in fusidic acid resistance percentages among MRSA isolates in the Netherlands. Materials and methods: Data on routine bacteriological cultures between 2016 and 2023 from 30 laboratories were extracted from the national surveillance system on antimicrobial resistance (ISIS–AR). Fusidic acid resistance percentages per year were calculated both overall and per age group for all MRSA isolates, and more specific, for the subset of MRSA isolates from wound/pus/skin samples collected by general practitioners (WPS-GP). Trends were determined using logistic regression and compared with trends among MSSA isolates. Results: We found an increase in fusidic acid resistance among MRSA isolates from 15% (2016) to 29% (2023) (P < 0.001), which differed significantly (P < 0.001) from the trend among MSSA isolates (10%–12%). An increase was also found in MRSA WPS-GP isolates, both among young children and the population of 13–64 years old, but not among elderly. The trends remained significant after exclusion of isolates associated with known fusidic acid-resistant MRSA outbreaks, both among MRSA isolates overall (OR = 1.10, 95% CI: 1.07–1.14, P < 0.001) and among MRSA WPS-GP isolates (OR = 1.14, 1.07–1.21, P < 0.001). Conclusions: In conclusion, an increasing trend in fusidic acid resistance was found among MRSA isolates. Since impaired treatment for impetigo might ease the spread of (fusidic acid-resistant) MRSA, extra vigilance is warranted.
- 30 October 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (6) , dlaf229
Open AccessIncreasing trend in fusidic acid resistance among MRSA isolates in the Netherlands, 2016–23
Objectives: Recently, several MRSA community outbreaks occurred in the Netherlands, including one caused by an impetigo-causing MRSA strain resistant to fusidic acid. Since fusidic acid and flucloxacillin are the main treatment options for impetigo, increasing resistance limits treatment possibilities. We examined trends in fusidic acid resistance percentages among MRSA isolates in the Netherlands. Materials and methods: Data on routine bacteriological cultures between 2016 and 2023 from 30 laboratories were extracted from the national surveillance system on antimicrobial resistance (ISIS–AR). Fusidic acid resistance percentages per year were calculated both overall and per age group for all MRSA isolates, and more specific, for the subset of MRSA isolates from wound/pus/skin samples collected by general practitioners (WPS-GP). Trends were determined using logistic regression and compared with trends among MSSA isolates. Results: We found an increase in fusidic acid resistance among MRSA isolates from 15% (2016) to 29% (2023) (P < 0.001), which differed significantly (P < 0.001) from the trend among MSSA isolates (10%–12%). An increase was also found in MRSA WPS-GP isolates, both among young children and the population of 13–64 years old, but not among elderly. The trends remained significant after exclusion of isolates associated with known fusidic acid-resistant MRSA outbreaks, both among MRSA isolates overall (OR = 1.10, 95% CI: 1.07–1.14, P < 0.001) and among MRSA WPS-GP isolates (OR = 1.14, 1.07–1.21, P < 0.001). Conclusions: In conclusion, an increasing trend in fusidic acid resistance was found among MRSA isolates. Since impaired treatment for impetigo might ease the spread of (fusidic acid-resistant) MRSA, extra vigilance is warranted.
- Open Access
Increasing trend in fusidic acid resistance among MRSA isolates in the Netherlands, 2016-2023
Synopsis: Objectives: Recently, several methicillin-resistant Staphylococcus aureus (MRSA) community outbreaks occurred in the Netherlands, including one caused by an impetigo-causing MRSA strain resistant to fusidic acid. Since fusidic acid and flucloxacillin are the main treatment options for impetigo, increasing resistance limits treatment possibilities. We examined trends in fusidic acid resistance levels among MRSA isolates in the Netherlands. Methods: Data on routine bacteriological cultures between 2016-2023 from 30 laboratories were extracted from the national surveillance system on antimicrobial resistance (ISIS-AR). Fusidic acid resistance rates per year were calculated both overall and per age group for all MRSA isolates, and more specific, for the subset of MRSA isolates from wound/pus/skin samples collected by general practitioners (WPS-GP-samples). Trends were determined using logistic regression and compared with trends among methicillin-susceptible S. aureus (MSSA) isolates. Results: We found an increasing trend in fusidic acid resistance among MRSA isolates from 15% in 2016 to 30% in 2023 (p<0.001) which differed significantly from the trend among MSSA isolates (p<0.001). An increase was also found in MRSA WPS-GP-samples, both among young children and the population of 13-64 years old, but not among elderly. The trends remained significant after exclusion of isolates associated with known fusidic acid-resistant MRSA outbreaks, both among MRSA isolates overall (OR = 1.10, 95% CI: 1.07-1.14, p<0.001) and among MRSA WPS-GP-samples (OR = 1.14, 1.07-1.21, p<0.001). Conclusions: In conclusion, an increasing trend in fusidic acid resistance was found among MRSA isolates. Since impaired treatment for impetigo might ease the spread of (fusidic acid-resistant) MRSA, extra vigilance is warranted.
Open AccessIncreasing trend in fusidic acid resistance among MRSA isolates in the Netherlands, 2016-2023
Synopsis: Objectives: Recently, several methicillin-resistant Staphylococcus aureus (MRSA) community outbreaks occurred in the Netherlands, including one caused by an impetigo-causing MRSA strain resistant to fusidic acid. Since fusidic acid and flucloxacillin are the main treatment options for impetigo, increasing resistance limits treatment possibilities. We examined trends in fusidic acid resistance levels among MRSA isolates in the Netherlands. Methods: Data on routine bacteriological cultures between 2016-2023 from 30 laboratories were extracted from the national surveillance system on antimicrobial resistance (ISIS-AR). Fusidic acid resistance rates per year were calculated both overall and per age group for all MRSA isolates, and more specific, for the subset of MRSA isolates from wound/pus/skin samples collected by general practitioners (WPS-GP-samples). Trends were determined using logistic regression and compared with trends among methicillin-susceptible S. aureus (MSSA) isolates. Results: We found an increasing trend in fusidic acid resistance among MRSA isolates from 15% in 2016 to 30% in 2023 (p<0.001) which differed significantly from the trend among MSSA isolates (p<0.001). An increase was also found in MRSA WPS-GP-samples, both among young children and the population of 13-64 years old, but not among elderly. The trends remained significant after exclusion of isolates associated with known fusidic acid-resistant MRSA outbreaks, both among MRSA isolates overall (OR = 1.10, 95% CI: 1.07-1.14, p<0.001) and among MRSA WPS-GP-samples (OR = 1.14, 1.07-1.21, p<0.001). Conclusions: In conclusion, an increasing trend in fusidic acid resistance was found among MRSA isolates. Since impaired treatment for impetigo might ease the spread of (fusidic acid-resistant) MRSA, extra vigilance is warranted.
- Open Access
- 14 December 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (50) , 2300152
Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
Background: The COVID-19 pandemic resulted in adaptation in infection control measures, increased patient transfer, high occupancy of intensive cares, downscaling of non-urgent medical procedures and decreased travelling.Aim: To gain insight in the influence of these changes on antimicrobial resistance (AMR) prevalence in the Netherlands, a country with a low AMR prevalence, we estimated changes in demographics and prevalence of six highly resistant microorganisms (HRMO) in hospitalised patients in the Netherlands during COVID-19 waves (March–June 2020, October 2020–June 2021, October 2021–May 2022 and June–August 2022) and interwaves (July–September 2020 and July–September 2021) compared with pre-COVID-19 (March 2019–February 2020).Methods: We investigated data on routine bacteriology cultures of hospitalised patients, obtained from 37 clinical microbiological laboratories participating in the national AMR surveillance. Demographic characteristics and HRMO prevalence were calculated as proportions and rates per 10,000 hospital admissions.Results: Although no significant persistent changes in HRMO prevalence were detected, some relevant non-significant patterns were recognised in intensive care units. Compared with pre-COVID-19 we found a tendency towards higher prevalence of meticillin-resistantStaphylococcus aureusduring waves and lower prevalence of multidrug-resistantPseudomonas aeruginosaduring interwaves. Additionally, during the first three waves, we observed significantly higher proportions and rates of cultures withEnterococcus faecium(pooled 10% vs 6% and 240 vs 120 per 10,000 admissions) and coagulase-negative Staphylococci (pooled 21% vs 14% and 500 vs 252 per 10,000 admissions) compared with pre-COVID-19.Conclusion: We observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic.
- 14 December 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (50) , 2300152
Open AccessImpact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
Background: The COVID-19 pandemic resulted in adaptation in infection control measures, increased patient transfer, high occupancy of intensive cares, downscaling of non-urgent medical procedures and decreased travelling.Aim: To gain insight in the influence of these changes on antimicrobial resistance (AMR) prevalence in the Netherlands, a country with a low AMR prevalence, we estimated changes in demographics and prevalence of six highly resistant microorganisms (HRMO) in hospitalised patients in the Netherlands during COVID-19 waves (March–June 2020, October 2020–June 2021, October 2021–May 2022 and June–August 2022) and interwaves (July–September 2020 and July–September 2021) compared with pre-COVID-19 (March 2019–February 2020).Methods: We investigated data on routine bacteriology cultures of hospitalised patients, obtained from 37 clinical microbiological laboratories participating in the national AMR surveillance. Demographic characteristics and HRMO prevalence were calculated as proportions and rates per 10,000 hospital admissions.Results: Although no significant persistent changes in HRMO prevalence were detected, some relevant non-significant patterns were recognised in intensive care units. Compared with pre-COVID-19 we found a tendency towards higher prevalence of meticillin-resistantStaphylococcus aureusduring waves and lower prevalence of multidrug-resistantPseudomonas aeruginosaduring interwaves. Additionally, during the first three waves, we observed significantly higher proportions and rates of cultures withEnterococcus faecium(pooled 10% vs 6% and 240 vs 120 per 10,000 admissions) and coagulase-negative Staphylococci (pooled 21% vs 14% and 500 vs 252 per 10,000 admissions) compared with pre-COVID-19.Conclusion: We observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic.
- Open Access
- 15 December 2022
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 27 (50) , 2200896-16
Multidrug-resistant organisms in patients from Ukraine in the Netherlands, March to August 2022
Since March 2022, there has been an emergence of multidrug-resistant organisms (MDRO) in the Netherlands in patients originating from Ukraine (58 patients, 75 isolates). For about half of these patients, recent hospitalisation in Ukraine was reported. Genomic surveillance revealed that the majority of the MDRO represent globally spread epidemic lineages and that 60% contain New Delhi metallo-β-lactamase (NDM) genes. Professionals should be aware of an increase in such MDRO associated with migration and medical evacuation of people from Ukraine.
- 15 December 2022
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 27 (50) , 2200896-16
Open AccessMultidrug-resistant organisms in patients from Ukraine in the Netherlands, March to August 2022
Since March 2022, there has been an emergence of multidrug-resistant organisms (MDRO) in the Netherlands in patients originating from Ukraine (58 patients, 75 isolates). For about half of these patients, recent hospitalisation in Ukraine was reported. Genomic surveillance revealed that the majority of the MDRO represent globally spread epidemic lineages and that 60% contain New Delhi metallo-β-lactamase (NDM) genes. Professionals should be aware of an increase in such MDRO associated with migration and medical evacuation of people from Ukraine.
- Open Access
- 29 September 2022
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (11) , 3205-3208
A genetic cluster of OXA-244 carbapenemase-producing Escherichia coli ST38 with putative uropathogenicity factors in the Netherlands
Carbapenemase-producing Enterobacterales (CPE) represent an increasing global problem. Since 2016, the carbapenemase oxacillinase (OXA)-244, a single amino-acid variant of OXA-48 and present in Escherichia coli ST38, has been recognized as an emerging carbapenemase variant in several European countries. This prompted the ECDC to publish a rapid risk assessment in February 2021 with a follow-up in July.1 The increase of OXA-244 was also observed in the Netherlands after analysis of the data from the Dutch national CPE surveillance. For the Dutch CPE surveillance, medical microbiology laboratories are requested to send isolates suspected of carbapenemase production, with a meropenem MIC of ≥0.25 mg/L and/or an imipenem MIC of ≥1 mg/L, or evidence of carbapenemase production, to the National Institute for Public Health and the Environment. Illumina next-generation sequencing (NGS) was performed on all isolates testing positive for carbapenemase production, from persons with a personal identifier code present to be able to detect multiple isolates from the same person.2 Between January 2016 and June 2021, from 1203 unique CPE isolates (unique combination of species and carbapenemase gene per person), NGS results were available. Of these, 394 (33%; 394/1203) isolates were E. coli and NGS data were used for Clermont phylotyping,3 classical MLST, whole-genome (wg)MLST analysis using an in-house E. coli wgMLST scheme, and core SNP analysis [Figure 1 and Figure S1(a and b), available as Supplementary data at JAC Online] .4 Among the 394 sequenced carbapenemase-producing E. coli isolates, 85 were MLST ST38, of which 30 contained blaOXA-244. Seventeen of these 30 OXA-244-producing ST38 E. coli isolates formed a genetic cluster based on wgMLST and was termed EcoCluster-023. A genetic wgMLST cluster is defined as ≥2 isolates that differ by ≤25 wgMLST alleles.4 The 17 EcoCluster-023 isolates differed by 1 to 21 wgMLST alleles from each other [Figure 1(b)]. In addition, core SNP analysis revealed 1 to 62 SNP differences among the 17 EcoCluster-023 isolates. [Figure S1(a and b) ]. The wgMLST allelic variation and SNP differences may be explained since isolates were from cultures taken between August 2016 and May 2021, with 13 (76%) isolates from 2020 and 2021. The 17 isolates were derived from 17 different patients, and were submitted by 13 different laboratories from eight different provinces. The median age of the patients was 54 years (range 8 to 92) and 10 (59%) patients were women. Nine (53%) isolates were cultured from urine, and the other eight from rectal swabs. This percentage of isolates derived from urine cultures was considerably higher than the 80 (21.2%) among the other 377 carbapenemase-producing E. coli isolates from this study excluding this cluster. All EcoCluster-023 isolates produced carbapenemase, as tested with the carbapenem inactivation method.5 The MIC of meropenem was below 1.5 mg/L for all isolates, as determined by Etest, therefore all isolates were susceptible according to EUCAST [Figure 1(c)]. Information on risk factors was available for 16 patients. There was no evidence for direct patient-to-patient transmission in this group. Eight (50%) persons had a known connection with Middle Eastern countries, Turkey in five patients and Syria in three. This was either as recent hospitalization in the previous 2 months (n = 2) or up to a year ago (n = 3), or as country of birth (n = 6, including three with previous hospitalization there). Recent hospitalization abroad up to 2 months previous, is considered a risk factor in Dutch national guidelines. The prevalence of OXA-244 in Middle Eastern countries is unknown.
- 29 September 2022
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (11) , 3205-3208
Open AccessA genetic cluster of OXA-244 carbapenemase-producing Escherichia coli ST38 with putative uropathogenicity factors in the Netherlands
Carbapenemase-producing Enterobacterales (CPE) represent an increasing global problem. Since 2016, the carbapenemase oxacillinase (OXA)-244, a single amino-acid variant of OXA-48 and present in Escherichia coli ST38, has been recognized as an emerging carbapenemase variant in several European countries. This prompted the ECDC to publish a rapid risk assessment in February 2021 with a follow-up in July.1 The increase of OXA-244 was also observed in the Netherlands after analysis of the data from the Dutch national CPE surveillance. For the Dutch CPE surveillance, medical microbiology laboratories are requested to send isolates suspected of carbapenemase production, with a meropenem MIC of ≥0.25 mg/L and/or an imipenem MIC of ≥1 mg/L, or evidence of carbapenemase production, to the National Institute for Public Health and the Environment. Illumina next-generation sequencing (NGS) was performed on all isolates testing positive for carbapenemase production, from persons with a personal identifier code present to be able to detect multiple isolates from the same person.2 Between January 2016 and June 2021, from 1203 unique CPE isolates (unique combination of species and carbapenemase gene per person), NGS results were available. Of these, 394 (33%; 394/1203) isolates were E. coli and NGS data were used for Clermont phylotyping,3 classical MLST, whole-genome (wg)MLST analysis using an in-house E. coli wgMLST scheme, and core SNP analysis [Figure 1 and Figure S1(a and b), available as Supplementary data at JAC Online] .4 Among the 394 sequenced carbapenemase-producing E. coli isolates, 85 were MLST ST38, of which 30 contained blaOXA-244. Seventeen of these 30 OXA-244-producing ST38 E. coli isolates formed a genetic cluster based on wgMLST and was termed EcoCluster-023. A genetic wgMLST cluster is defined as ≥2 isolates that differ by ≤25 wgMLST alleles.4 The 17 EcoCluster-023 isolates differed by 1 to 21 wgMLST alleles from each other [Figure 1(b)]. In addition, core SNP analysis revealed 1 to 62 SNP differences among the 17 EcoCluster-023 isolates. [Figure S1(a and b) ]. The wgMLST allelic variation and SNP differences may be explained since isolates were from cultures taken between August 2016 and May 2021, with 13 (76%) isolates from 2020 and 2021. The 17 isolates were derived from 17 different patients, and were submitted by 13 different laboratories from eight different provinces. The median age of the patients was 54 years (range 8 to 92) and 10 (59%) patients were women. Nine (53%) isolates were cultured from urine, and the other eight from rectal swabs. This percentage of isolates derived from urine cultures was considerably higher than the 80 (21.2%) among the other 377 carbapenemase-producing E. coli isolates from this study excluding this cluster. All EcoCluster-023 isolates produced carbapenemase, as tested with the carbapenem inactivation method.5 The MIC of meropenem was below 1.5 mg/L for all isolates, as determined by Etest, therefore all isolates were susceptible according to EUCAST [Figure 1(c)]. Information on risk factors was available for 16 patients. There was no evidence for direct patient-to-patient transmission in this group. Eight (50%) persons had a known connection with Middle Eastern countries, Turkey in five patients and Syria in three. This was either as recent hospitalization in the previous 2 months (n = 2) or up to a year ago (n = 3), or as country of birth (n = 6, including three with previous hospitalization there). Recent hospitalization abroad up to 2 months previous, is considered a risk factor in Dutch national guidelines. The prevalence of OXA-244 in Middle Eastern countries is unknown.
- Open Access
- 21 June 2022
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (4) , 616-623
Semiautomated surveillance of deep surgical site infections after colorectal surgeries: A multicenter external validation of two surveillance algorithms
Objective: Automated surveillance methods increasingly replace or support conventional (manual) surveillance; the latter is labor intensive and vulnerable to subjective interpretation. We sought to validate 2 previously developed semiautomated surveillance algorithms to identify deep surgical site infections (SSIs) in patients undergoing colorectal surgeries in Dutch hospitals.Design: Multicenter retrospective cohort study.Methods: From 4 hospitals, we selected colorectal surgery patients between 2018 and 2019 based on procedure codes, and we extracted routine care data from electronic health records. Per hospital, a classification model and a regression model were applied independently to classify patients into low- or high probability of having developed deep SSI. High-probability patients need manual SSI confirmation; low-probability records are classified as no deep SSI. Sensitivity, positive predictive value (PPV), and workload reduction were calculated compared to conventional surveillance.Results: In total, 672 colorectal surgery patients were included, of whom 28 (4.1%) developed deep SSI. Both surveillance models achieved good performance. After adaptation to clinical practice, the classification model had 100% sensitivity and PPV ranged from 11.1% to 45.8% between hospitals. The regression model had 100% sensitivity and 9.0%–14.9% PPV. With both models, <25% of records needed review to confirm SSI. The regression model requires more complex data management skills, partly due to incomplete data.Conclusions: In this independent external validation, both surveillance models performed well. The classification model is preferred above the regression model because of source-data availability and less complex data-management requirements. The next step is implementation in infection prevention practices and workflow processes.
- 21 June 2022
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (4) , 616-623
Open AccessSemiautomated surveillance of deep surgical site infections after colorectal surgeries: A multicenter external validation of two surveillance algorithms
Objective: Automated surveillance methods increasingly replace or support conventional (manual) surveillance; the latter is labor intensive and vulnerable to subjective interpretation. We sought to validate 2 previously developed semiautomated surveillance algorithms to identify deep surgical site infections (SSIs) in patients undergoing colorectal surgeries in Dutch hospitals.Design: Multicenter retrospective cohort study.Methods: From 4 hospitals, we selected colorectal surgery patients between 2018 and 2019 based on procedure codes, and we extracted routine care data from electronic health records. Per hospital, a classification model and a regression model were applied independently to classify patients into low- or high probability of having developed deep SSI. High-probability patients need manual SSI confirmation; low-probability records are classified as no deep SSI. Sensitivity, positive predictive value (PPV), and workload reduction were calculated compared to conventional surveillance.Results: In total, 672 colorectal surgery patients were included, of whom 28 (4.1%) developed deep SSI. Both surveillance models achieved good performance. After adaptation to clinical practice, the classification model had 100% sensitivity and PPV ranged from 11.1% to 45.8% between hospitals. The regression model had 100% sensitivity and 9.0%–14.9% PPV. With both models, <25% of records needed review to confirm SSI. The regression model requires more complex data management skills, partly due to incomplete data.Conclusions: In this independent external validation, both surveillance models performed well. The classification model is preferred above the regression model because of source-data availability and less complex data-management requirements. The next step is implementation in infection prevention practices and workflow processes.
- Open Access
- 25 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
National surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing Pseudomonas aeruginosa ST111 in the Netherlands between 2015 and 2017
Verona Integron-encoded Metallo-beta-lactamase (VIM) is the most frequently-encountered carbapenemase in the healthcare-related pathogen Pseudomonas aeruginosa. In the Netherlands, a low-endemic country for antibiotic-resistant bacteria, no national surveillance data on the prevalence of carbapenemase-producing P. aeruginosa (CPPA) was available. Therefore, in 2016, a national surveillance pilot study was initiated to investigate the occurrence, molecular epidemiology, genetic characterization, and resistomes of CPPA among P. aeruginosa isolates submitted by medical microbiology laboratories (MMLs) throughout the country. From 1221 isolates included in the study, 124 (10%) produced carbapenemase (CIM-positive); of these, the majority (95, 77%) were positive for the blaVIM gene using PCR. Sequencing was performed on 112 CIM-positive and 56 CIM-negative isolates (n = 168), and genetic clustering revealed that 75/168 (45%) isolates were highly similar. This genetic cluster, designated Group 1, comprised isolates that belonged to high-risk sequence type ST111/serotype O12, had similar resistomes, and all but two carried the blaVIM-2 allele on an identical class 1 integron. Additionally, Group 1 isolates originated from around the country (i.e. seven provinces) and from multiple MMLs. In conclusion, the Netherlands had experienced a nationwide, inter-institutional, clonal outbreak of VIM-2-producing P. aeruginosa for at least three years, which this pilot study was crucial in identifying. A structured, national surveillance program is strongly advised to monitor the spread of Group 1 CPPA, to identify emerging clones/carbapenemase genes, and to detect transmission in and especially between hospitals in order to control current and future outbreaks.
- 25 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Open AccessNational surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing Pseudomonas aeruginosa ST111 in the Netherlands between 2015 and 2017
Verona Integron-encoded Metallo-beta-lactamase (VIM) is the most frequently-encountered carbapenemase in the healthcare-related pathogen Pseudomonas aeruginosa. In the Netherlands, a low-endemic country for antibiotic-resistant bacteria, no national surveillance data on the prevalence of carbapenemase-producing P. aeruginosa (CPPA) was available. Therefore, in 2016, a national surveillance pilot study was initiated to investigate the occurrence, molecular epidemiology, genetic characterization, and resistomes of CPPA among P. aeruginosa isolates submitted by medical microbiology laboratories (MMLs) throughout the country. From 1221 isolates included in the study, 124 (10%) produced carbapenemase (CIM-positive); of these, the majority (95, 77%) were positive for the blaVIM gene using PCR. Sequencing was performed on 112 CIM-positive and 56 CIM-negative isolates (n = 168), and genetic clustering revealed that 75/168 (45%) isolates were highly similar. This genetic cluster, designated Group 1, comprised isolates that belonged to high-risk sequence type ST111/serotype O12, had similar resistomes, and all but two carried the blaVIM-2 allele on an identical class 1 integron. Additionally, Group 1 isolates originated from around the country (i.e. seven provinces) and from multiple MMLs. In conclusion, the Netherlands had experienced a nationwide, inter-institutional, clonal outbreak of VIM-2-producing P. aeruginosa for at least three years, which this pilot study was crucial in identifying. A structured, national surveillance program is strongly advised to monitor the spread of Group 1 CPPA, to identify emerging clones/carbapenemase genes, and to detect transmission in and especially between hospitals in order to control current and future outbreaks.